Bio

I am a pharmacological scientist with over 10 years of extensive experience in cancer Biology , and neuroimmunology research. My work spans cancer experimental molecular therapeutics using In vitro and In vivo techniques and cellular immunology. My current work aims to increase the understanding of pediatric acute onset neuropsychiatric disorder (PANS) disease molecular mechanism through studying the immunophenotypic changes in the peripheral blood patient with PANS. I hope that this work will pave the way to novel treatment strategies.

Institute Affiliations

Honors & Awards

  • Scholar in training award, American association for cancer research (March 2020)
  • Best poster presentation award, Emerging health Care and Advancement in Toxicology international conference (September 1st 2016)
  • Michael A. Jenike Young Investigator Award, International OCD foundation (September 2023)

Boards, Advisory Committees, Professional Organizations

  • Review Editor for Experimental Pharmacology and Drug Discovery, Frontiers in Pharmacology Journal (2021 - Present)
  • Associate member, American association for cancer research (2017 - Present)

Stanford Advisors

Contact

  • Academic
    nhussei@stanford.edu
    University - Scholar Department: School of Medicine Position: Postdoctoral Scholar

Additional Info

All Publications

  • A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform. Science advances Jiang, Y., Sanyal, M., Hussein, N. A., Baghdasaryan, A., Zhang, M., Wang, F., Ren, F., Li, J., Zhu, G., Meng, Y., Adamska, J. Z., Mellins, E., Dai, H. 2025; 11 (6): eadp5539

    Abstract

    The COVID-19 pandemic caused a global health crisis that resulted in millions of deaths. Effective vaccines have played central roles in curtailing the pandemic. Here, we developed a down-converting near-infrared IIb (NIR-IIb; 1500 to 1700 nanometers) luminescent, pure NaErF4@NaYF4 rare-earth nanoparticle (pEr) as vaccine carriers. The pEr nanoparticles were coated with three layers of cross-linked biocompatible polymers (pEr-P3; ~55 nanometers) and conjugated to the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Upon subcutaneous injection of the pEr-P3-RBD nanovaccine in mice, in vivo NIR-IIb imaging revealed active vaccine trafficking and migration to lymph nodes through lymphatic vessels. Two doses of the adjuvant-free vaccine elicited long-lasting (>7 months) high titers of serum viral neutralization antibody and anti-RBD immunoglobulin G, along with robust RBD-specific germinal center B cells and T follicular helper cells. We devised in vivo NIR-II molecular imaging of RBD-specific cells in lymph nodes, opening noninvasive assessments of vaccine-elicited immune responses longitudinally.

    View details for DOI 10.1126/sciadv.adp5539

    View details for PubMedID 39919189

  • Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA Singer, N., Breitman, M., Haghiac, M., Gordesky, L., Reese, J., Lewis, S., Barnboym, E., Hussein, N., Lasalvia, S., Mellins, E., Bonfield, T., Anthony, D., Caplan, A., Lazarus, H. WILEY. 2023: 2575-2576

    View details for Web of Science ID 001190014302314

https://orcid.org/0000-0003-2270-7739